# US 2020/0390766 A1 · Pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390766 A1
- Document ID: US20200390766A1
- Status: Published application
- Kind: A1
- Application number: 16/899,638
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-13
- Assignees: Kowa Company, Ltd.
- Applicants: Kowa Company, Ltd.
- Inventors: Kentaro Mikami; Rie Ishida; Takashi Nakagawa
- Web page: https://patentgrep.com/patent/US20200390766A1

## CPC

- A61K 31/504: forming part of bridged ring systems
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

[Problem to be solved] The present invention addresses the problem of providing a pharmaceutical composition for the prevention and/or treatment of diseases related to pulmonary fibrosis. [Solution] Provided is a pharmaceutical composition for the prevention and/or treatment of diseases involving pulmonary fibrosis, in which the active ingredient is 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, or a salt thereof, or a solvate of these.

## Claims

### Claim 1

A pharmaceutical composition comprising 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, a salt, a solvate or a solvate of the salt thereof for preventing and/or treating a pulmonary fibrosis related disorder.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pulmonary fibrosis related disorder is a disease selected from the group consisting of idiopathic interstitial pneumonia, diffuse interstitial pneumonia, post-inflammatory pulmonary fibrosis, usual interstitial pneumonia, pulmonary fibrosis, diffuse alveolar damage, autoimmune disease and interstitial pneumonia caused by the autoimmune disease, pneumoconiosis, chronic hypersensitivity pneumonia and interstitial pneumonia caused by the chronic hypersensitivity pneumonia, drug-induced pneumonia and interstitial pneumonia caused by the drug-induced pneumonia, viral infectious disease and interstitial pneumonia caused by the viral infectious disease, radiation pneumonitis and interstitial pneumonia caused by the radiation pneumonitis, sarcoidosis and interstitial pneumonia caused by the sarcoidosis, pulmonary involvements associated with collagen vascular disease and interstitial pneumonia caused by the disease, and systemic scleroderma and interstitial pneumonia caused by the systemic scleroderma.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pulmonary fibrosis related disorder is a disease selected from the group consisting of usual interstitial pneumonia, interstitial pneumonia caused by autoimmune disease, interstitial pneumonia caused by drug-induced pneumonia, interstitial pneumonia caused by viral infectious disease, interstitial pneumonia caused by radiation pneumonitis, interstitial pneumonia caused by sarcoidosis, interstitial pneumonia caused by pulmonary involvements associated with collagen vascular disease, interstitial pneumonia caused by systemic scleroderma, and idiopathic interstitial pneumonia.

### Claim 4 (depends on 2, 3)

The pharmaceutical composition according to claim 2 or 3, wherein the idiopathic interstitial pneumonia is a disease selected from the group consisting of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, cryptogenic organizing pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, acute interstitial pneumonia, and lymphocytic interstitial pneumonia.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pulmonary fibrosis related disorder is a disease selected from the group consisting of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, cryptogenic organizing pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, acute interstitial pneumonia, and lymphocytic interstitial pneumonia.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pulmonary fibrosis related disorder is idiopathic pulmonary fibrosis.
